Author

John Robert Hyngstrom

University of UtahORCID 0000-0002-4833-3838Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:zebrafish· 1

Frequent Co-Authors

Allie H. GrossmanniD· 1 shared Amanda JiangiD· 1 shared Anastasia Prokofyeva· 1 shared Carly A. BeckeriD· 1 shared David Henry LumiD· 1 shared Dekker C. DeaconiD· 1 shared Emilio Cortes-SancheziD· 1 shared Eric A. SmithiD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Allie H. GrossmannORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment

Eric A. Smith, R. L. Belote, Nelly M. Cruz, Tarek E. Moustafa, Carly A. Becker, Amanda Jiang, Shukran Alizada, Anastasia Prokofyeva, Tsz Yin Chan, Tori A. Seasor, Michael A. Balatico, Emilio Cortes-Sanchez, David Henry Lum, John Robert Hyngstrom, Hanlin Zeng, , Robert L. Judson‐Torres

This study shows that dual FGFR/VEGFR inhibition causes regression of acral melanoma by targeting the tumor microenvironment rather than directly killing cancer cells.

Journal of Experimental & Clinical Cancer Research · Dec 3, 2024Peer-reviewedCancer Biology